Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate CS231295 in advanced solid tumors.
CS231295: A Promising Multi-Target Inhibitor
CS231295 is a multi-target protein kinase inhibitor that has shown an excellent ability to penetrate the blood-brain barrier. This characteristic is particularly significant as it positions CS231295 to potentially demonstrate unique application advantages and differentiated potential in the treatment of multiple solid tumors, with a special focus on those affecting the brain. The drug’s ability to cross the blood-brain barrier could offer new therapeutic options for patients with brain tumors, where traditional treatments may be limited by their inability to reach the target site effectively.-Fineline Info & Tech
